The FDA has approved a new at-home HPV self-collection kit for cervical cancer screening, marking a major step toward expanding screening access for patients who are unscreened or under-screened. The test is expected to be available by prescription and covered by Medicare and Medicaid, creating new opportunities for community health centers to integrate self-collection into preventive care.
← Back to all resources
FDA Clears Onclarity HPV Self-Collection Kit
April 16, 2026